Psychopharmacology

, Volume 179, Issue 3, pp 521–528 | Cite as

Nicotinic–serotonergic drug interactions and attentional performance in rats

  • Amir H. Rezvani
  • D. Patrick Caldwell
  • Edward D. Levin
Original Investigation

Abstract

Rationale

Both central serotonergic and nicotinic systems play important roles in a variety of neurobehavioral functions; however, the interactions of these two systems have not been fully characterized. The current study served to determine the impact of a relatively selective 5-HT2A receptor antagonist, ketanserin, on attentional function in rats and the interactions of ketanserin with nicotine administration.

Methods

A standard operant visual signal detection task was used to assess sustained attention. In expt 1, adult female Sprague–Dawley rats (n=39) were injected subcutaneously (SC) with a dose range of ketanserin (0, 0.25, 0.5 and 1 mg/kg). In expt 2, the interactions of acute ketanserin (0, 1 and 2 mg/kg, SC) and acute nicotine (0, 25 and 50 μg/kg, SC) were assessed. In expt 3, the interaction of acute ketanserin (0, 1 and 2 mg/kg, SC) and chronic nicotine (5 mg/kg per day, SC for 4 weeks via osmotic pump) was characterized. Using an operant visual signal detection task, three possible outcomes (dependent variables) were measured in each trial: percent hit, percent correct rejection, and response omissions.

Results

Ketanserin, when given alone, did not have a significant effect on either percent hit or percent correct rejection. Acute administration of 25 μg/kg nicotine significantly improved percent hit (i.e. improvement in choice accuracy), an effect that was reversed by acute administration of 1 mg/kg ketanserin. Chronic nicotine infusion for 28 consecutive days significantly increased percent correct rejection (i.e. improvement in choice accuracy) without development of tolerance, an effect which was reversed by an acute dose of 2 mg/kg ketanserin.

Conclusions

These data suggest a functional interaction between nicotine and 5-HT2A receptor antagonist ketanserin.

Keywords

Attention Ketanserin Serotonin Cognition Signal detection task Serotonin antagonists Nicotine 

Notes

Acknowledgements

We greatly appreciate the expertise of Dr. Philip Bushnell and Charles Hamm of the US-EPA in assisting with the set up and the maintenance of the operant system. The authors would like to thank Joy Limpuangthip for her excellent editorial skills and Ana Pocivavsek for her assistance with the project. This research was supported by the National Institute of Mental Health grant MH64494.

References

  1. Antoniou K, Berkis S, Saranti M, Stathis P, Rimikis M, Papadopoulou-Daifoti Z (2000) The effects of antipsychotic drugs on serotonergic activity in the rat hippocampus. Eur Neuropharmacol 10:315–324Google Scholar
  2. Buhot MC (1997) Serotonin receptors in cognitive behaviors. Curr Opin Neurobiol 7:243–254CrossRefPubMedGoogle Scholar
  3. Bushnell P (1998) Behavioral approaches to the assessment of attention in animals. Psychopharmacology 138:231–259CrossRefPubMedGoogle Scholar
  4. Bushnell PJ, Oshiro WM, Padnos BK (1997) Detection of visual signals by rats: effects of chlordiazepoxide and cholinergic and adrenergic drugs on sustained attention. Psychopharmacology 134:230–241CrossRefPubMedGoogle Scholar
  5. Damaj MI, Glennon RA, Martin BR (1994) Involvement of the serotonergic system in the hypoactive and antinociceptive effects of nicotine in mice. Brain Res Bull 33:199–203CrossRefPubMedGoogle Scholar
  6. Engberg G, Hajos M (1994) Nicotine-Induced activation of locus coeruleus neurons an analysis of peripheral versus central induction. Naunyn Schmiedeberg’s Arch Pharmacol 349:443–446Google Scholar
  7. Friedman JI, Adler DN, Howanitz E, Harvey PD, Brenner G, Temporini H, White L, Parrella M, Davis KL (2003) A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry 51:349–357CrossRefGoogle Scholar
  8. Grilly DM, Simon BB, Levin ED (2000) Nicotine enhances stimulus detection performance of middle- and old-aged rats: a longitudinal study. Pharmacol Biochem Behav 65:665–670Google Scholar
  9. Jäkälä P, Sirvio J, Jolkkonen J, Riekkinen P Jr, Acsady L, Riekkinen P (1992) The effects of p-chlorophenylalanine-induced serotonin synthesis inhibition and muscarinic blockade on the performance of rats in a 5-choice serial reaction time task. Behav Brain Res 51:29–40PubMedGoogle Scholar
  10. Lawrence AD, Sahakian BJ (1995) Alzheimer’s disease, attention, and the cholinergic system. Alzheimer Dis Assoc Disord 9:43–49PubMedGoogle Scholar
  11. Levin E, Wilson W, Rose J, McEvoy J (1996a) Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 15:429–436CrossRefPubMedGoogle Scholar
  12. Levin ED, Conners CK, Sparrow E, Hinton S, Meck W, Rose JE, Ernhardt D, March J (1996b) Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology 123:55–63PubMedGoogle Scholar
  13. Levin ED, Conners CK, Silva D, Hinton SC, Meck W, March J, Rose JE (1998) Transdermal nicotine effects on attention. Psychopharmacology 140:135–141CrossRefPubMedGoogle Scholar
  14. Levin ED, Conners CK, Silva D, Canu W, March J (2001) Effects of chronic nicotine and methylphenidate in adults with ADHD. Exp Clin Psychopharmacol 9:83–90Google Scholar
  15. Lichtensteiger W, Ribary U, Schlumpf M, Odermatt B, Widmer R (1988) Prenatal adverse effects of nicotine on the developing brain. Prog Brain Res 73:137–157PubMedGoogle Scholar
  16. Lubow R (1997) Latent inhibition as a measure of learned intention: some problems and solutions. Behav Brain Res 88:75–83CrossRefPubMedGoogle Scholar
  17. Mar C, Smith DA, Sarter M (1996) Behavioral vigilance in schizophrenia: evidence for hyperattentional processing. Br J Psychiatry 169:781–789PubMedGoogle Scholar
  18. McGaughy J, Decker MW, Sarter M (1999) Enhancement of sustained attention performance by the nicotinic acetylcholine receptor agonist ABT-418 in intact but not basal forebrain-lesioned rats. Psychopharmacology 144:175–182CrossRefPubMedGoogle Scholar
  19. Meltzer H (1995) Atypical antipsychotic drugs. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven, New York, pp 1277–1286Google Scholar
  20. Mirza NR, Bright JL (2001) Nicotine-induced enhancements in the five-choice serial reaction time task in rats are strain-dependent. Psychopharmacology 154:8–12CrossRefPubMedGoogle Scholar
  21. Mirza NR, Stolerman IP (1998) Nicotine enhances sustained attention in the rat under specific task conditions. Psychopharmacology 138:266–274CrossRefPubMedGoogle Scholar
  22. Mirza NR, Pei Q, Stolerman IP, Zetterstrom TSC (1996) The nicotinic receptor agonists (−)-nicotine and isoarecolone differ in their effects on dopamine release in the nucleus accumbens. Eur J Pharmacol 295:207–210CrossRefPubMedGoogle Scholar
  23. Muir JL, Everitt BJ, Robbins TW (1995) Reversal of visual attentional dysfunction following lesions of the cholinergic basal forebrain by physostigmine and nicotine but not by the 5-HT3 receptor antagonist, ondansetron. Psychopharmacology 118:82–92PubMedGoogle Scholar
  24. Murrin LC, Ferrer JR, Wanyun Z, Haley NJ (1987) Nicotine administration to rats: methodological considerations. Life Sci 40:1699–1708CrossRefPubMedGoogle Scholar
  25. Peeke SC, Peeke HVS (1984) Attention, memory, and cigarette smoking. Psychopharmacology 84:205–216CrossRefPubMedGoogle Scholar
  26. Poyurovsky M, Koren D, Gonopolsky I, Schneidman M, Fuchs C, Weizman A, Weizman R (2003) Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. Eur Neuropsychopharmacol 13:123–128Google Scholar
  27. Rezvani AH, Levin ED (2003a) Nicotine interactions with the NMDA glutaminergic antagonist dizocilpine and attentional function. Eur J Pharmacol 465:83–90CrossRefPubMedGoogle Scholar
  28. Rezvani AH, Levin ED (2003b) Nicotine-alcohol interactions and attentional performance on an operant visual signal detection task in female rats. Pharmacol Biochem Behav 76:75–83CrossRefPubMedGoogle Scholar
  29. Rezvani AH, Levin ED (2004) Nicotine-antipsychotic drug interactions and attentional performance in female rats. Eur J Pharmacol 486:175–182CrossRefPubMedGoogle Scholar
  30. Rezvani AH, Bushnell PJ, Burkholder JM, Glasgow HB, Levin ED (2001) Specificity of cognitive impairment from Pfiesteria piscicida exposure in rats: attention and visual function vs behavioral plasticity. Neurotoxicol Teratol 23:609–616CrossRefPubMedGoogle Scholar
  31. Rezvani AH, Bushnell P, Levin ED (2002) Nicotine and mecamylamine effects on choice accuracy in an operant signal detection task. Psychopharmacology 164:369–375CrossRefPubMedGoogle Scholar
  32. Ruiu S, Marchese G, Saba P, Gessa G, Pani L (2000) The 5-HT2 antagonist ritanserin blocks dopamine reuptake in the rat frontal cortex. Mol Psychiatry 5:673–677CrossRefPubMedGoogle Scholar
  33. Ruotsalainen S, Sirvio J, Jäkälä P, Puumala T, MacDonald E, Riekkinen P Sr (1997) Differential effects of three 5-HT receptor antagonists on the performance of rats in attentional and working memory tasks. Eur Neuropsychopharmacol 7:99–108Google Scholar
  34. Sahakian B, Jones G, Levy R, Gray J, Warburton D (1989) The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of Alzheimer type. Br J Psychiatry 154:797–800PubMedGoogle Scholar
  35. Sanders-Bush E, Mayer SE (2001) 5-Hydroxytryptamine (serotonin): receptor agonists and antagonists. In: Hardman JG, Limbird L, Goodman Gilman AG (eds) The pharmacological basis of therapeutics, 10th edn. McGraw-Hill, New York, pp 269–290Google Scholar
  36. Sarter M, Givens B, Bruno JP (2001) The cognitive neuroscience of sustained attention: where top-down meets bottom-up. Brain Res Rev 35:146–160CrossRefPubMedGoogle Scholar
  37. Seth P, Cheeta S, Tucci S, File SE (2002) Nicotine–serotonergic interactions in brain and behavior. Pharmacol Biochem Behav 71:795–805CrossRefPubMedGoogle Scholar
  38. Slotkin TA (1992) Prenatal exposure to nicotine: what can we learn from animal models?. In: Zagon IS, Slotkin TA (eds) Maternal substance abuse and the developing nervous system. Academic, New York, pp 97–124Google Scholar
  39. Solomon P, Kiney C, Scott D (1978) Disruption of latent inhibition following systemic administration of parachlorophenylalanine (PCPA). Physiol Behav 20:265–271CrossRefPubMedGoogle Scholar
  40. Solomon P, Nichols G, Kiernan J, Kamor R, Kaplan L (1980) Differential effects of lesions in medial and dorsal raphe of the rat: latent inhibition and septohippocampal serotonin levels. J Comp Physiol Psychol 94:145–154PubMedGoogle Scholar
  41. Stolerman IP, Mirza NR, Hahn B, Shoaib M (2000) Nicotine in an animal model of attention. Eur J Pharmacol 393:147–154CrossRefPubMedGoogle Scholar
  42. Summers KL, Giacobini E (1995) Effects of local and repeated systemic administration of (−)nicotine on extracellular levels of acetylcholine, norepinephrine, dopamine, and serotonin in rat cortex. Neurochem Res 20:753–759PubMedGoogle Scholar
  43. Trauth JA, Seidler FJ, McCook EC, Slotkin TA (1999) Adolescent nicotine exposure causes persistent upregulation of nicotinic cholinergic receptors in rat brain regions. Brain Res 851:9–19CrossRefPubMedGoogle Scholar
  44. Turchi J, Holley LA, Sarter M (1995) Effects of nicotinic acetylcholine receptor ligands on behavioral vigilance in rats. Psychopharmacology 118:195–205PubMedGoogle Scholar
  45. Wadenberg M, Salmi P, Jimenez P, Svensson T, Ahlenius S (1996) Enhancement of antipsychotic-like properties of the dopamine D2 receptor antagonist, raclopride, by the additional treatment with the 5-HT2 receptor blocking agent, ritanserin, in the rat. Eur Neuropsychopharmacol 6:305–310Google Scholar
  46. Warburton DM, Rusted JM, Fowler J (1992) A comparison of the attentional and consolidation hypotheses for the facilitation of memory by nicotine. Psychopharmacology 108:443–447PubMedGoogle Scholar
  47. White HK, Levin ED (1999) Chronic four week nicotine skin patch treatment effects on cognitive performance in Alzheimer’s disease. Psychopharmacology 143:158–165CrossRefPubMedGoogle Scholar
  48. Williams G, Rao S, Goldman-Rakic P (2002) The physiological role of 5-HT2A receptors in working memory. J Neurosci 22:2843–2854Google Scholar
  49. Wonnacott S (1997) Presynaptic nicotinic ACh receptors. Trends Neurosci 20:92–98CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Amir H. Rezvani
    • 1
  • D. Patrick Caldwell
    • 1
  • Edward D. Levin
    • 1
  1. 1.Department of Psychiatry and Behavioral SciencesDuke University Medical CenterDurhamUSA

Personalised recommendations